To study expressions and clinical significances of the glutathione S-transferase π (GST-π) and P170 glycoprotein in paclitaxel combined with cisplatin in treatment of epithelial ovarian cancer (EOC).

From June 2012 to June 2016, a total of 60 cases of EOC patients who hospitalized and treated in Putuo District Maternal and Child Health Hospital of Shanghai were recruited in this study. They were randomly divided into research group (n=30, treated by paclitaxel combined with cisplatin) and control group (n=30, treated by paclitaxel alone) by random number table method.Positive expressions of GST-π and P170 glycoprotein, curative effects, serological indicators, and incidence of adverse reactions after chemotherapy between two groups were analyzed by statistical methods. There were no significant differences between two groups among age, Federation International of Gynecology and Obstetrics (FIGO) clinical stage and relapse rate of EOC (P>0.05). The procedure of this study was consistent with ethical standard established by the committee of investigation in human beings of Putuo District Maternal and Child Health Hospital of Shanghai. Patients were informed of grouping and their written informed consents were obtained before clinical studies.

After chemotherapy, positive expressions of GST-π and P170 glycoprotein in research group were remarkably lower than those in control group, and there were significant differences (χ²=4.28, 4.34; P<0.05). The levels improvement degrees of serological indicators such as carbohydrate antigen 125 (CA₁₂₅), transforming growth factor (TNF)-α, and soluble interleukin-2 receptor (SIL-2R) in research group were better than those in control group, and there were significant differences (t=5.14, 6.53, 5.86; P<0.05). Total incidence of adverse reactions of chemotherapy in research group was remarkably lower than that in control group, overall effective rate of chemotherapy in research group was much higher than that in control group, and all the differences were statistically significant (χ²=4.44, 5.52; P<0.05).

Chemotherapy sensitivity in treatment of EOC with paclitaxel combined with cisplatin is much higher than the treatment with paclitaxel alone, and total incidence of adverse reaction is remarkably lower, and overall effective rate of chemotherapy is much higher than the treatment with paclitaxel alone. Whether positive expressions of GST-π and P170 glycoprotein as a judging criteria of overall effective in treatment of EOC are worthy of clinical application or not, multi-center and large-sample randomized controlled trial will be needed to confirm.